Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer

Inclusion Criteria: * Age ≥ 18 years old * Histologically or cytologically confirmed adenocarcinoma of the breast * Locally recurrent or metastatic disease * HER 2 negative status * Requiring a first or a second-line chemotherapy for locally recurrent or metastatic disease. * Prior first line chemotherapy not containing Docetaxel * Measurable or evaluable disease according to RECIST 1.1 criteria * Allowed prior chemotherapy as follows : * Docetaxel in the neoadjuvant or adjuvant setting is allowed provided that relapse has been observed more than 12 months after the end of docetaxel treatment * Bevacizumab in 1st line is allowed with a wash-out of 4 weeks, with recovery to NCI-CTCAE v3.0 toxicity * ECOG performance status 0-1 * Adequate bone marrow, hepatic and renal functions as evidence by the following: * Hemoglobin ≥ 10 G/100 mL * Neutrophils count ≥ 1500 /mm3 * Platelets ≥ 100 000 /mm3 * Total bilirubin ≤ ULN (ULN:Upper Limit of Normal) * SGOT/SGPT ≤ 1.5 x ULN (≤ 2.5 x ULN in case of hepatic metastasis) * Serum alkaline phosphatase ≤ 2.5 x ULN * Creatinin clearance ≥ 45 ml/min or creatinin ≤ 1.5 x ULN * Proteinuria \< CTCAE grade 2 * Coagulation parameters: International normalised ratio (INR) ≤ 2, prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 50% of deviation of institutional ULN * Effective contraception for patients (male and female) with reproductive potential during their entire participation in the study and during 3 months af…